NCT06345794View on ClinicalTrials.gov

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

June 18, 2024

Study Completion Date

June 18, 2024

Conditions
Healthy
Interventions
DRUG

LY4100511 (DC-853)

Administered orally.

DRUG

Itraconazole

Administered orally.

DRUG

Fluconazole

Administered orally.

DRUG

Carbamazepine

Administered orally.

Trial Locations (1)

78209

ICON San Antonio Clinical Research Unit, San Antonio

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY

NCT06345794 - A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants | Biotech Hunter | Biotech Hunter